Jump to content

Mesothelioma Survival Statistics: Difference between revisions

From WikiMesothelioma — Mesothelioma Knowledge Base
← Older edit
MesotheliomaSupport (talk | contribs)
Bots, Bureaucrats, Administrators
2,015 edits
VisualWikitext
Bot edit
Converting duplicate page to redirect for SEO cleanup
Tag: New redirect
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{#seo:
#REDIRECT [[Survival Statistics]]
|title=Mesothelioma Survival Rates & Statistics 2026: Complete Prognosis Guide
|description=Current mesothelioma survival statistics show 15% 5-year survival overall. Learn factors affecting prognosis and how treatment advances are improving outcomes.
|keywords=mesothelioma survival rate, mesothelioma prognosis, mesothelioma life expectancy, mesothelioma statistics, mesothelioma survival by stage
|image=mesothelioma-survival-statistics.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-01-14
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Survival Statistics
|-
| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic; color:#333333;" | Current Data Through 2026
|-
| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" | 5-Year Survival (All)
| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" | 15%
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" | Localized Stage
| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" | 23% (5-year)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" | Peritoneal Type
| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" | 65% (5-year)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6; color:#333333;" | Immunotherapy OS
| style="padding:10px; border-bottom:1px solid #dee2e6; background:#ffffff; color:#333333;" | 18.1 months median
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333;" | New Treatments
| style="padding:10px; background:#ffffff; color:#333333;" | 86% disease control (VT3989)
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | <span data-nosnippet class="noai-content">[https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]</span>
|}
 
== Executive Summary ==
 
Mesothelioma survival rates have improved significantly with advances in immunotherapy, targeted therapy, and surgical techniques, though the disease remains serious. According to the National Cancer Institute SEER database, the overall 5-year relative survival rate for mesothelioma is approximately 12%, with dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Mesothelioma Cancer Stat Facts], National Cancer Institute SEER</ref> Peritoneal mesothelioma patients achieving complete surgical cytoreduction now experience 5-year survival rates exceeding 65%, while patients treated with the immunotherapy combination nivolumab plus ipilimumab show 23% 3-year survival compared to 15% with chemotherapy alone.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref> Understanding these statistics helps patients and families make informed treatment decisions and pursue appropriate legal compensation for asbestos exposure.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
 
== Key Facts ==
{| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Mesothelioma Survival Statistics 2026
|-
| style="padding:15px; background:#f8f9fa; color:#333333;" |
* '''Overall 5-Year Survival:''' 12% across all stages and types combined<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], National Cancer Institute SEER</ref>
* '''Localized Disease:''' 23% 5-year survival rate when cancer remains contained
* '''Regional Spread:''' 15% 5-year survival when cancer has spread to nearby structures
* '''Distant Metastasis:''' 11% 5-year survival for advanced disease
* '''Peritoneal vs. Pleural:''' 65% versus 12% 5-year survival rates
* '''Epithelioid Histology:''' 14-18 months median survival, approximately 14% 5-year survival
* '''Sarcomatoid Histology:''' 4-8 months median survival, approximately 4% 5-year survival
* '''Immunotherapy Benefit:''' 18.1 months median OS versus 14.1 months with chemotherapy
* '''Non-Epithelioid Improvement:''' Immunotherapy doubles survival (18.1 vs. 8.8 months)
* '''Specialized Centers:''' Survival rates 2.5 times higher than national averages<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>
* '''Complete Cytoreduction:''' 104 months median survival for peritoneal patients with CC-0
* '''Gender Disparity:''' Women show approximately 50% better survival than men
|}
 
== What Are Current Mesothelioma Survival Rates by Stage? ==
 
Stage at diagnosis remains one of the most important prognostic factors for mesothelioma patients. The National Cancer Institute's SEER database, which represents the most comprehensive cancer statistics in the United States, categorizes survival by localized, regional, and distant disease stages rather than traditional TNM staging.<ref>[https://www.cancer.gov/about-cancer/diagnosis-staging/staging Cancer Staging], National Cancer Institute</ref>
 
Localized mesothelioma, where the cancer remains confined to the pleura or peritoneum without spread to lymph nodes or distant sites, shows 23% 5-year relative survival.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma], Danziger & De Llano</ref> Regional disease, indicating spread to nearby lymph nodes or adjacent structures, demonstrates 15% 5-year survival. Distant metastatic disease, where cancer has spread to remote organs or distant lymph nodes, shows 11% 5-year survival.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/stages/ Stages of Mesothelioma], Mesothelioma Lawyer Center</ref>
 
The AJCC Cancer Staging System Version 9, now applied to cases diagnosed from 2025 forward, provides more detailed staging criteria that better predict outcomes.<ref>[https://www.cancer.gov/about-cancer/diagnosis-staging/staging/staging-fact-sheet Staging Fact Sheet], National Cancer Institute</ref> Early-stage patients (stages I-II) who undergo aggressive multimodal treatment including surgery typically achieve median survival of 21-24 months, with select patients surviving 5 years or longer.
 
{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" | "Stage at diagnosis significantly influences both treatment options and outcomes. We work to ensure families understand how staging affects not only prognosis but also their legal timeline for pursuing compensation."
|-
| style="padding:5px 25px 20px; text-align:right; color:#333333;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}
 
== How Does Mesothelioma Type Affect Survival? ==
 
The location where mesothelioma develops dramatically influences survival outcomes.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs Peritoneal Mesothelioma], Danziger & De Llano</ref> Peritoneal mesothelioma, arising in the abdominal lining, maintains substantially better prognosis than pleural mesothelioma affecting the lung lining.
 
'''Peritoneal Mesothelioma''' demonstrates 65% 5-year survival compared to just 12% for pleural disease.<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref> One-year survival rates are 92% for peritoneal versus 73% for pleural patients. This dramatic difference reflects both the disease biology and availability of highly effective cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC).<ref>[https://www.mesotheliomalawyercenter.org/peritoneal-mesothelioma-cancer/ Peritoneal Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>
 
'''Pleural Mesothelioma''' represents approximately 80% of all cases and carries median survival of 12-21 months depending on stage, histology, and treatment approach.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/pleural/ Pleural Mesothelioma], MesotheliomaAttorney.com</ref> However, patients treated at specialized mesothelioma centers achieve significantly better outcomes, with some programs reporting survival rates 2.5 times national averages.
 
'''Pericardial and Testicular Mesothelioma''' are rare variants representing less than 3% of cases combined. Testicular mesothelioma paradoxically shows the best prognosis among all types when treated surgically, while pericardial mesothelioma carries poor prognosis due to its location around the heart.<ref>[https://mesothelioma.net/pericardial-mesothelioma/ Pericardial Mesothelioma], Mesothelioma.net</ref>
 
== What Role Does Cell Type Play in Prognosis? ==
 
Mesothelioma cell type (histology) represents another critical prognostic factor that significantly influences treatment options and survival expectations.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref>
 
'''Epithelioid Mesothelioma''' accounts for 50-70% of cases and carries the most favorable prognosis.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/epithelioid/ Epithelial Mesothelioma], MesotheliomaAttorney.com</ref> Median survival ranges from 14-18 months, with approximately 14% 5-year survival. This cell type responds best to chemotherapy, immunotherapy, and surgical interventions.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/types/epithelial/ Epithelioid Mesothelioma], Mesothelioma Lawyer Center</ref>
 
'''Sarcomatoid Mesothelioma''' represents 10-20% of cases and demonstrates the poorest outcomes, with median survival of only 4-8 months and approximately 4% 5-year survival.<ref>[https://dandell.com/lawyers/paul-danziger/ Paul Danziger], Danziger & De Llano</ref> Historically resistant to chemotherapy, this aggressive subtype now shows dramatically improved outcomes with immunotherapy. The CheckMate 743 trial demonstrated median survival of 18.1 months versus 8.8 months with chemotherapy for non-epithelioid disease—effectively doubling survival.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/sarcomatoid/ Sarcomatoid Mesothelioma Guide], MesotheliomaAttorney.com</ref>
 
'''Biphasic Mesothelioma''' contains both epithelioid and sarcomatoid cells, with prognosis depending on the ratio of each cell type.<ref>[https://dandell.com/lawyers/rod-de-llano/ Rod de Llano], Danziger & De Llano</ref> Tumors with predominantly epithelioid features behave more favorably than those with dominant sarcomatoid components.
 
{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ Immunotherapy Breakthrough for Non-Epithelioid Disease''' The 2025 ASCO Guidelines now recommend nivolumab plus ipilimumab as the preferred first-line treatment for non-epithelioid mesothelioma based on the dramatic survival benefit demonstrated in CheckMate 743 (hazard ratio 0.46).
|}
 
== How Has Immunotherapy Changed Survival Outcomes? ==
 
The FDA approval of nivolumab plus ipilimumab in October 2020 marked the first new systemic treatment for mesothelioma in over 15 years and has substantially improved survival expectations.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Immunotherapy for Mesothelioma], U.S. Food and Drug Administration</ref>
 
The CheckMate 743 trial, with 3-year follow-up data representing the most mature efficacy analysis available, demonstrated median overall survival of 18.1 months with immunotherapy versus 14.1 months with chemotherapy (hazard ratio 0.73).<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref> Three-year survival rates reached 23% versus 15%, with 3-year progression-free survival of 14% versus just 1% for chemotherapy.
 
Critically, 28% of patients who responded to immunotherapy maintained their response at 3 years, compared to 0% in the chemotherapy group—demonstrating the potential for durable disease control in selected patients.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/treatment/ Mesothelioma Treatment Guide], Mesothelioma Lawyer Center</ref>
 
The FDA also approved pembrolizumab with chemotherapy in September 2024, providing another immunotherapy option for mesothelioma patients.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref>
 
{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5; color:#333333;" | "The immunotherapy revolution has fundamentally changed how we approach mesothelioma cases. Patients now have treatment options that weren't available even five years ago, which affects both their medical decisions and their legal strategy."
|-
| style="padding:5px 25px 20px; text-align:right; color:#333333;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}
 
== What New Treatments Are Improving Survival in 2026? ==
 
Several breakthrough therapies are demonstrating remarkable efficacy and may further improve survival outcomes in the coming years.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>
 
'''VT3989 (TEAD Inhibitor)''' received FDA Fast Track Designation in October 2025 after demonstrating exceptional results in heavily pretreated patients. This first-in-class therapy achieved 86% disease control rate and 32% objective response rate, with median progression-free survival of approximately 10 months—more than double the 15-week benchmark for salvage chemotherapy. A Phase 3 registrational trial is planned for early 2026.
 
'''CAR-T Cell Therapy''' continues showing remarkable durability. Memorial Sloan Kettering's mesothelin-targeted CAR-T program has demonstrated responses lasting beyond 5 years in early patients, with one patient first treated in 2019 remaining disease-controlled as of late 2024. Clinical trials for CAR-T therapy are actively recruiting.<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&intr=CAR-T Mesothelioma CAR-T Trials], ClinicalTrials.gov</ref>
 
'''BNT327/PM8002 (Bispecific Antibody)''' demonstrated 51.6% confirmed objective response rate and 90.3% disease control rate in Phase 2 trials, representing one of the highest response rates seen in unresectable mesothelioma.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma], Mesothelioma Lawyer Center</ref>
 
'''ATOMIC-meso (ADI-PEG20)''' achieved its primary endpoint for non-epithelioid mesothelioma, demonstrating a 29% reduction in death risk and quadrupling 3-year survival compared to placebo plus chemotherapy.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>
 
== How Does Specialized Treatment Center Care Affect Survival? ==
 
Treatment at specialized mesothelioma centers dramatically improves survival outcomes compared to community cancer centers. Research published in multiple studies demonstrates that patients treated at NCI-designated comprehensive cancer centers achieve significantly better outcomes.<ref>[https://www.cancer.gov/research/nci-role/cancer-centers NCI-Designated Cancer Centers], National Cancer Institute</ref>
 
'''Brigham and Women's Hospital''' (International Mesothelioma Program) has documented patients surviving 20+ years, including one patient who survived 29 years after extrapleural pneumonectomy before passing in 2025.<ref>[https://www.brighamandwomens.org/lung-center/thoracic-surgery/international-mesothelioma-program International Mesothelioma Program], Brigham and Women's Hospital</ref> The program has performed over 1,448 mesothelioma surgeries and offers the proprietary Four-Gene Ratio Test for personalized treatment selection.<ref>[https://dandell.com/settlements/ Mesothelioma Settlements], Danziger & De Llano</ref>
 
'''MD Anderson Cancer Center''' reports peritoneal mesothelioma outcomes with 40% objective response rate and 85% one-year survival using atezolizumab plus bevacizumab.<ref>[https://www.mdanderson.org/cancer-types/mesothelioma.html Mesothelioma at MD Anderson], MD Anderson Cancer Center</ref> Their Ki-67 biomarker analysis showed patients with Ki-67 ≤9% achieving median survival of 86.6 months versus just 10.3 months for those with Ki-67 >9%.
 
'''Moffitt Cancer Center''' reports survival rates approximately 2.5 times national averages: 73% one-year and 12% five-year for pleural mesothelioma, with 65% five-year survival for peritoneal disease (increasing to 80% with CRS-HIPEC plus chemotherapy).<ref>[https://www.moffitt.org/cancers/mesothelioma/ Mesothelioma at Moffitt], Moffitt Cancer Center</ref>
 
'''Memorial Sloan Kettering''' published the world's largest single-center outcomes study (945 patients) and demonstrated 51% disease control with tazemetostat for BAP1-mutant disease.<ref>[https://www.mskcc.org/cancer-care/types/mesothelioma Mesothelioma at MSK], Memorial Sloan Kettering Cancer Center</ref>
 
{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ Specialized Center Advantage''' Patients treated at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes through access to clinical trials, multidisciplinary teams, and high surgical volumes.
|}
 
== What Is the Prognosis for Peritoneal Mesothelioma with CRS-HIPEC? ==
 
Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) has transformed peritoneal mesothelioma from universally fatal to potentially curable in selected patients.<ref>[https://mesothelioma.net/heated-intraperitoneal-chemotherapy/ Heated Intraperitoneal Chemotherapy (HIPEC)], Mesothelioma.net</ref>
 
The completeness of cytoreduction represents the paramount prognostic factor:<ref>[https://dandell.com/mesothelioma-lawyers/ Top-Rated Mesothelioma Lawyers], Danziger & De Llano</ref>
 
* '''CC-0 (Complete Cytoreduction):''' 104 months median survival
* '''CC-1 (Minimal Residual):''' 30 months median survival
* '''CC-2 (Incomplete):''' 2.7 months median survival
 
Peritoneal Cancer Index (PCI), measuring tumor distribution across abdominal regions, also strongly predicts outcomes:<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/ Mesothelioma Cancer], Mesothelioma Lawyer Center</ref>
 
* '''PCI 0-20:''' 103 months median survival
* '''PCI 21-39:''' 33 months median survival
 
The 2025 PSM Consortium Consensus Guidelines emphasize complete cytoreduction as the treatment goal, with cisplatin plus doxorubicin emerging as the preferred HIPEC regimen (53 months mean survival versus 38 months with single agents).<ref>[https://mesothelioma.net/peritonectomy/ Peritonectomy/Cytoreductive Surgery], Mesothelioma.net</ref>
 
== How Do Demographic Factors Influence Survival? ==
 
Patient demographics significantly affect mesothelioma outcomes, with notable disparities by gender and age.<ref>[https://mesothelioma.net/mesothelioma-life-expectancy/ Mesothelioma Life Expectancy and Survival Rate], Mesothelioma.net</ref>
 
'''Gender Disparity:''' Women demonstrate approximately 50% better 5-year survival (19-21%) compared to men (8-9%).<ref>[https://www.mesotheliomalawyercenter.org/blog/new-study-shows-higher-survival-rate-among-women-mesothelioma/ Study Shows Higher Mesothelioma Survival Rates in Women], Mesothelioma Lawyer Center</ref> This difference may reflect hormonal factors, later average age at diagnosis for women, different exposure patterns (often secondary exposure through household contact), and higher likelihood of epithelioid histology in female patients.
 
'''Age at Diagnosis:''' Patients diagnosed before age 50 show 75% one-year survival compared to 44% for those over 65.<ref>[https://mesothelioma.net/mesothelioma-death-rate/ Mesothelioma Death Rate], Mesothelioma.net</ref> Younger patients more often tolerate aggressive multimodal treatment including surgery, improving their long-term outcomes.
 
'''Performance Status:''' Patients with good functional status (ECOG 0-1) consistently demonstrate better treatment tolerance and survival across all mesothelioma types and stages.<ref>[https://dandell.com/mesothelioma-veterans/ Veterans & Mesothelioma Claims], Danziger & De Llano</ref>
 
== Why Does Early Legal Action Matter for Mesothelioma Patients? ==
 
Understanding survival statistics is essential not only for treatment planning but also for protecting legal rights and family financial security.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>
 
Mesothelioma patients may be entitled to compensation from multiple sources:<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-claims-law/ Mesothelioma Claims], Mesothelioma Lawyer Center</ref>
 
* '''Asbestos Trust Funds:''' Over $30 billion available across 60+ active trusts
* '''Personal Injury Lawsuits:''' Against negligent asbestos manufacturers and employers
* '''Veterans Benefits:''' VA disability compensation, DIC, and healthcare<ref>[https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/ Asbestos Exposure and VA Benefits], U.S. Department of Veterans Affairs</ref>
* '''Workers' Compensation:''' For occupational asbestos exposure
 
Statutes of limitations vary by state but typically range from 1-6 years from diagnosis.<ref>[https://dandell.com/mesothelioma/mesothelioma-lawsuits-texas/ How Mesothelioma Lawsuits Work], Danziger & De Llano</ref> While improved survival means more time for treatment, it does not extend legal deadlines. Experienced mesothelioma attorneys can pursue compensation while patients focus on treatment and quality of life.<ref>[https://mesotheliomaattorney.com/mesothelioma/compensation/ Mesothelioma Compensation Guide], MesotheliomaAttorney.com</ref>
 
{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠ Important Legal Consideration''' Improved survival through newer treatments can extend the time available for pursuing legal compensation, but statutes of limitations still apply. Consulting with experienced mesothelioma attorneys early ensures families preserve all legal options.
|}
 
== Get Help Today ==
 
If you or a loved one has been diagnosed with mesothelioma, understanding survival statistics is just the first step.<ref>[https://dandell.com/ Asbestos & Mesothelioma Lawyers], Danziger & De Llano</ref> Connecting with specialized treatment centers and experienced legal professionals can help maximize both treatment outcomes and financial recovery.
 
'''Call Danziger & De Llano today at (866) 222-9990''' for a free, confidential case evaluation. Our team has decades of experience helping mesothelioma patients and families navigate both the medical and legal aspects of this disease.<ref>[https://www.mesotheliomalawyercenter.org/ Find Top Mesothelioma Attorneys], Mesothelioma Lawyer Center</ref>
 
{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ What You Can Expect:'''
* Free case evaluation with no obligation
* Identification of all potential asbestos exposure sources
* Connection with leading mesothelioma treatment specialists
* Pursuit of maximum compensation from all available sources
* No upfront costs—we only get paid if you recover compensation
|}
 
== Related Wiki Articles ==
 
'''Treatment Centers:'''
* [[MD Anderson Mesothelioma Program]]
* [[Memorial Sloan Kettering Cancer Center]]
* [[Brigham International Mesothelioma Program]]
* [[Moffitt Cancer Center]]
* [[Mayo Clinic Cancer Center]]
 
'''Resources:'''
* [[Clinical Trials]] — Current trial opportunities
* [[Mesothelioma Treatment Costs]] — Financial planning guide
* [[Asbestos Trust Funds]] — Compensation information
* [[Veterans Benefits]] — VA claims and healthcare
 
'''High-Risk Occupations:'''
* [[Insulation Workers]]
* [[Boilermakers]]
* [[Marine Engineering Workers]]
* [[Norfolk Naval Shipyard]]
 
== References ==
 
<references />
 
[[Category:Mesothelioma]]
[[Category:Prognosis]]
[[Category:Medical Information]]
[[Category:Treatment]]
[[Category:Survival Statistics]]

Latest revision as of 01:09, 12 February 2026

Redirect to:

Retrieved from "https://wikimesothelioma.com/w/index.php?title=Mesothelioma_Survival_Statistics&oldid=1143"